Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alfi, Inc. stock logo
ALFIW
Alfi
$0.00
$0.00
$2.88
N/AN/A6,051 shsN/A
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
$6.43
-0.5%
$2.50
$6.35
$8.31
$378.25M4.61839,705 shs968,954 shs
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
$26.70
-1.3%
$27.44
$20.12
$30.92
$15.26B0.765.78 million shs3.61 million shs
Venture Global, Inc. stock logo
VG
Venture Global
$9.67
-5.7%
$0.00
$8.62
$25.50
$23.40BN/A9.31 million shs7.87 million shs
10 Best Stocks to Own in 2025 Cover

Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alfi, Inc. stock logo
ALFIW
Alfi
0.00%0.00%0.00%0.00%0.00%
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
-0.77%-3.74%+1,814.83%+2,118.77%+160.32%
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
-1.29%-3.09%-5.05%-11.06%+20.49%
Venture Global, Inc. stock logo
VG
Venture Global
-5.93%+6.26%-41.89%+966,999,900.00%+966,999,900.00%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alfi, Inc. stock logo
ALFIW
Alfi
N/AN/AN/AN/AN/AN/AN/AN/A
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
1.3638 of 5 stars
0.00.01.73.61.81.70.6
Venture Global, Inc. stock logo
VG
Venture Global
4.3835 of 5 stars
4.30.00.80.02.91.73.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alfi, Inc. stock logo
ALFIW
Alfi
0.00
N/AN/AN/A
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
0.00
N/AN/AN/A
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
0.00
N/AN/AN/A
Venture Global, Inc. stock logo
VG
Venture Global
2.64
Moderate Buy$17.5581.44% Upside

Current Analyst Ratings Breakdown

Latest VG, NLOK, BTX, and ALFIW Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/11/2025
Venture Global, Inc. stock logo
VG
Venture Global
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $11.00
3/11/2025
Venture Global, Inc. stock logo
VG
Venture Global
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $11.00
3/11/2025
Venture Global, Inc. stock logo
VG
Venture Global
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $18.00
3/10/2025
Venture Global, Inc. stock logo
VG
Venture Global
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$27.00 ➝ $20.00
3/7/2025
Venture Global, Inc. stock logo
VG
Venture Global
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$29.00 ➝ $20.00
3/7/2025
Venture Global, Inc. stock logo
VG
Venture Global
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$17.00 ➝ $15.00
3/7/2025
Venture Global, Inc. stock logo
VG
Venture Global
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$25.00 ➝ $16.00
2/18/2025
Venture Global, Inc. stock logo
VG
Venture Global
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$18.00
2/18/2025
Venture Global, Inc. stock logo
VG
Venture Global
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$20.00
2/18/2025
Venture Global, Inc. stock logo
VG
Venture Global
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Perform$17.00
(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alfi, Inc. stock logo
ALFIW
Alfi
$200.68KN/AN/AN/AN/AN/A
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
$40.69M9.30N/AN/AN/A
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
$2.82B5.42N/AN/AN/A
Venture Global, Inc. stock logo
VG
Venture Global
$4.97B4.71N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alfi, Inc. stock logo
ALFIW
Alfi
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
N/A-$2.27N/AN/AN/AN/AN/AN/A
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
N/A$1.4318.67N/AN/AN/AN/AN/A
Venture Global, Inc. stock logo
VG
Venture Global
N/AN/A0.004.100.29N/AN/AN/AN/A

Latest VG, NLOK, BTX, and ALFIW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/6/2025Q4 2024
Venture Global, Inc. stock logo
VG
Venture Global
$0.30$0.33+$0.03$0.33N/A$1.52 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alfi, Inc. stock logo
ALFIW
Alfi
N/AN/AN/AN/AN/A
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
$0.9114.15%N/AN/A N/A
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
$0.501.87%+44.22%34.97%N/A
Venture Global, Inc. stock logo
VG
Venture Global
$0.010.10%N/AN/AN/A

Latest VG, NLOK, BTX, and ALFIW Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/3/2025
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
Monthly$0.08623/14/20253/14/20253/31/2025
2/28/2025
Venture Global, Inc. stock logo
VG
Venture Global
quarterly$0.01650.44%3/10/20253/10/20253/31/2025
(Data available from 1/1/2013 forward)

Institutional Ownership

CompanyInstitutional Ownership
Alfi, Inc. stock logo
ALFIW
Alfi
N/A
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
26.00%
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
94.86%
Venture Global, Inc. stock logo
VG
Venture Global
N/A

Insider Ownership

CompanyInsider Ownership
Alfi, Inc. stock logo
ALFIW
Alfi
N/A
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
20.50%
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
3.30%
Venture Global, Inc. stock logo
VG
Venture Global
4.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alfi, Inc. stock logo
ALFIW
Alfi
40N/AN/ANot Optionable
Brooklyn ImmunoTherapeutics Inc stock logo
BTX
Brooklyn ImmunoTherapeutics
N/A58.83 millionN/ANo Data
NortonLifeLock Inc stock logo
NLOK
NortonLifeLock
N/A571.37 millionN/ANo Data
Venture Global, Inc. stock logo
VG
Venture Global
1,4002.42 billion2.31 billionN/A

Recent News About These Companies

Why Venture Global, Inc. (VG) Is Losing This Week?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alfi stock logo

Alfi NASDAQ:ALFIW

Alfi, Inc. provides interactive intelligent artificial intelligence and machine learning software solutions. Alfi, Inc. was formerly known as Lectrefy, Inc. and changed its name to Alfi, Inc. in January 2020. The company was founded in 2018 and is based in Miami Beach, Florida.

Brooklyn ImmunoTherapeutics stock logo

Brooklyn ImmunoTherapeutics NYSE:BTX

$6.43 -0.03 (-0.46%)
As of 03/13/2025 03:58 PM Eastern

Eterna Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. The company is headquartered in San Diego, CA.

NortonLifeLock stock logo

NortonLifeLock NASDAQ:NLOK

$26.70 -0.35 (-1.29%)
As of 03/12/2025

Gen Digital, Inc. engages in the provision of security, storage, and systems management solutions. The firm focuses on providing consumer cyber safety with its business solutions. The company was founded by Gary Hendrix in April 1982 and is headquartered in Tempe, AZ.

Venture Global stock logo

Venture Global NYSE:VG

$9.67 -0.58 (-5.66%)
As of 03/13/2025 03:58 PM Eastern

Venture Global has fundamentally reshaped the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. Our innovative and disruptive approach, which is both scalable and repeatable, allows us to bring LNG to a global market years faster and at a lower cost. We believe supplying this clean, affordable fuel promotes global energy security and is essential to meeting growing global demand. Natural gas is one of the most important resources worldwide and is required to generate reliable electricity that underpins economic development and drives industry. Once natural gas is supercooled to -260°F, it converts to liquid form and reduces to 1/600th of its original volume, enabling large quantities of natural gas to be loaded and shipped by LNG tankers. The resulting LNG can be transported to international markets that lack domestic supply, displacing more carbon intensive sources of energy such as coal, diesel, and heavy fuel oil, and serving as an integral part of a cleaner energy future. We believe our business model has demonstrated that in a competitive commodity market, lower cost and overall faster delivery wins market share. Our approach capitalizes on both of these advantages, supporting significant additional growth opportunities. Our Projects We are commissioning, constructing, and developing five natural gas liquefaction and export projects near the Gulf of Mexico in Louisiana, utilizing our unique “design one, build many” approach. Each project is designed or is being developed to include an LNG facility and associated pipeline systems that interconnect with several interstate and intrastate pipelines to enable the delivery of natural gas into the LNG facility. Our five current projects are being designed to deliver a total expected peak production capacity of 143.8 mtpa, which consists of an aggregate of 104.4 mtpa expected nameplate capacity and an aggregate of 39.4 mtpa of expected excess capacity. These amounts do not account for any potential bolt-on expansion liquefaction capacity. The expected nameplate capacity of our facilities measures the minimum operating performance thresholds guaranteed by the equipment providers, and the expected excess capacity represents the additional LNG that we aim to produce above such guaranteed amounts. Although COD has not yet occurred under the post-COD SPAs for any of our projects, we have been generating proceeds from the sale of commissioning cargos at the Calcasieu Project since the first quarter of 2022, and expect to do so at each of our other projects during commissioning prior to achieving COD for the relevant project or phase of a project. Our direct subsidiary, VGLNG, which owns all of our subsidiaries, was originally established in 2013 by our founders. As part of certain corporate reorganization transactions, or Reorganization Transactions, Venture Global, Inc. was formed in 2023 and became the 100% owner of VGLNG. We are a holding company and have no direct operations. All of our business operations are conducted through our subsidiaries, including VGLNG. Our principal asset is the equity interest in VGLNG, which, together with its subsidiaries, owns substantially all of our operating assets. As a result, we are dependent on the ability of our subsidiaries to generate revenues and to make loans, pay dividends and make other payments to generate the funds necessary to meet our financial obligations and to pay dividends to stockholders, if any. Our principal executive offices are located at 1001 19th Street North, Suite 1500, Arlington, VA.